Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals Inc (SLRX)
NASDAQ:SLRX
RESEARCH TOOLSreports
SLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $7.20
Previous CloseN/A
Volume13.28K
Average Volume (3M)366.00K
Market Cap
$1.22M
Enterprise Value$439.07K
Total Cash (Recent Filing)$2.43M
Total Debt (Recent Filing)$221.87K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.42
Shares Outstanding1,745,730
10 Day Avg. Volume724,889
30 Day Avg. Volume366,004
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
2.84%
Insiders
0.55% Mutual Funds
1.32% Other Institutional Investors
94.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRX FAQ
What was Salarius Pharmaceuticals Inc’s price range in the past 12 months?
Salarius Pharmaceuticals Inc lowest stock price was $0.69 and its highest was $7.20 in the past 12 months.
What is Salarius Pharmaceuticals Inc’s market cap?
Salarius Pharmaceuticals Inc’s market cap is $1.22M.
When is Salarius Pharmaceuticals Inc’s upcoming earnings report date?
Salarius Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Salarius Pharmaceuticals Inc’s earnings last quarter?
Salarius Pharmaceuticals Inc released its earnings results on Mar 24, 2025. The company reported -$1.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.016.
Is Salarius Pharmaceuticals Inc overvalued?
According to Wall Street analysts Salarius Pharmaceuticals Inc’s price is currently Overvalued.
Does Salarius Pharmaceuticals Inc pay dividends?
Salarius Pharmaceuticals Inc does not currently pay dividends.
What is Salarius Pharmaceuticals Inc’s EPS estimate?
Salarius Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Salarius Pharmaceuticals Inc have?
Salarius Pharmaceuticals Inc has 1,745,730 shares outstanding.
What happened to Salarius Pharmaceuticals Inc’s price movement after its last earnings report?
Salarius Pharmaceuticals Inc reported an EPS of -$1.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of Salarius Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SLRX
---
Company Description
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
---
SLRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aptevo Therapeutics
―
ReShape Lifesciences
―
Virpax Pharmaceuticals
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
---